Intro offer
100 days of Premium for just $10.
Try all Premium features for over 3 months and analyze stocks without limits.
Try 100 days for $10

$12.34
2.37%
NYSE, Sep 15, 04:00 pm EDT. Closed.
ISIN
VGG111961055
Symbol
BHVN

Biohaven Pharmaceutical Holding Company Ltd. Stock price

$12.34
-2.12 14.66% 1M
+2.70 28.01% 6M
+1.05 9.30% YTD
-1.40 10.19% 1Y
-6.76 35.39% 3Y
-123.65 90.93% 5Y
-5.16 29.49% 10Y
-5.16 29.49% 20Y
NYSE, Closing price Tue, Sep 15 2026
-0.30 2.37%
ISIN
VGG111961055
Symbol
BHVN
Industry

Is Biohaven Pharmaceutical Holding Company Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,142 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.9b
Enterprise Value
$1.9b
Net debt
positive
Cash
$267.9m
Shares outstanding
151.0m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
152.5
Financial Health
Equity Ratio
11.5%
Return on Equity
-1,418.9%
ROCE
-184.2%
ROIC
-471.2%
Debt/Equity
21.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-557.1m
EBIT
$-567.4m
Net Income
$-586.8m
Free Cash Flow
$-511.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
29.7%
EBIT
29.2%
Net Income
23.5%
Free Cash Flow
20.8%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-3.9
FCF per Share
$-3.4
Short interest
16.1%
Employees
274
Rev per Employee
$0.0

Biohaven Pharmaceutical Holding Company Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

18x Buy
78%
4x Hold
17%
1x Sell
4%

Analyst Opinions

23 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

Buy
78%
Hold
17%
Sell
4%

Financial data from Biohaven Pharmaceutical Holding Company Ltd.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 100 100
4% 4%
-
- Research and Development Expense 468 468
33% 33%
-
-557 -557
30% 30%
-
- Depreciation and Amortization 10 10
19% 19%
-
EBIT (Operating Income) EBIT -567 -567
29% 29%
-
Net Profit -587 -587
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about Biohaven Pharmaceutical Holding Company Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biohaven Pharmaceutical Holding Company Ltd. Stock News

Negative
Barrons
6 days ago
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
Negative
Investors Business Daily
6 days ago
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns.
Negative
Reuters
6 days ago
Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of ​its experimental epilepsy drug after rodent findings, sending its ‌shares down more than 13% in premarket trading.
More Biohaven Pharmaceutical Holding Company Ltd. News

Company Profile

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Head office Virgin Islands, British
CEO Dr. Coric
Employees 274
Founded 2022
Website www.biohaven.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today